• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inhibition of EP2 receptor suppresses tumor growth and chemoresistance of gastric cancer
In this study, we found that expression of EP2 receptor was significantly upregulated in gastric cancer. Inhibition of EP2 receptor reduced gastric cancer cell proliferation, induced cell cycle arrest proteins, and enhanced cell apoptosis. Moreover, knockdown of EP2 receptor by siRNA or antagonist sensitized gastric cancer cells to ECF. Silence of EP2 receptor also significantly abrogated gastric cancer growth in a mice model. Analysis revealed that CAV1 was a downstream target of EP2 receptor in gastric cancer. Our findings illustrated that blocking EP2 receptor reduced tumor growth and induced apoptosis in gastric cancer...
Source: Cell Research - November 16, 2022 Category: Cytology Authors: Vivian Yvonne Shin Michelle Xin Liu Jennifer Man-Ting Siu Ava Kwong Kent-Man Chu Source Type: research

Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy
ConclusionsCPLX1 may represent a biomarker for recurrence of gastric cancer and a target for therapy.
Source: Journal of Gastroenterology - June 21, 2022 Category: Gastroenterology Source Type: research

Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells
ConclusionStudy results demonstrate a mechanism where GCMSC-CM promotes GC chemoresistance by upregulating CTCF-PD-L1 and provide strong evidence in support of targeting CTCF-PD-L1 signaling as a strategy to prevent resistance in the clinic.
Source: Frontiers in Immunology - April 27, 2022 Category: Allergy & Immunology Source Type: research

Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer
ConclusionTMPRSS4 can be considered as a potential prognostic biomarker, especially for stage III, and a promising therapeutic target for GC.
Source: Journal of Gastrointestinal Surgery - August 11, 2021 Category: Surgery Source Type: research

Inhibition of USP11 sensitizes gastric cancer to chemotherapy via suppressing RhoA and Ras-mediated signaling pathways
CONCLUSIONS: Our work highlights the important role of USP11 in gastric cancer and therapeutic value of inhibiting USP11 to sensitize gastric cancer to chemotherapy.PMID:34332125 | DOI:10.1016/j.clinre.2021.101779
Source: Cell Research - July 31, 2021 Category: Cytology Authors: Hongfang Liu Mei Liu Bin He Qinghuan Li Source Type: research

Targeting cPLA2 α inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/β-catenin pathways
ConclusionsOur work demonstrates cPLA2 α inhibition as a therapeutic strategy to overcome chemo-resistance and highlights the association of cPLA2α and Ras in gastric cancer.
Source: Cancer Chemotherapy and Pharmacology - July 13, 2021 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 12, Pages 3463: DNAJA3/Tid1 Is Required for Mitochondrial DNA Maintenance and Regulates Migration and Invasion of Human Gastric Cancer Cells
Conclusions: Tid1 is required for mtDNA maintenance and regulates migration and invasion of gastric cancer cells. Tid1 deletion may be a poor prognostic factor in gastric cancers and could be further investigated for development of gastric cancer treatments.
Source: Cancers - November 20, 2020 Category: Cancer & Oncology Authors: Sheng-Fan Wang Kuo-Hung Huang Wei-Chuan Tseng Jeng-Fan Lo Anna Fen-Yau Li Wen-Liang Fang Chian-Feng Chen Tien-Shun Yeh Yuh-Lih Chang Yueh-Ching Chou Hung-Hsu Hung Hsin-Chen Lee Tags: Article Source Type: research

Role of Tropomyosin-related kinase B receptor and brain-derived neurotrophic factor in cancer.
Abstract The tropomyosin-related kinase B (TrkB) receptor is a member of the neurotrophic tyrosine kinase receptors family and, together with the brain-derived neurotrophic factor (BDNF), plays an important role in the development of breast cancer, lung cancer, neuroblastoma, colorectal cancer, leukemia, cervical cancer, gallbladder cancer, gastric cancer, kidney cancer, Ewing's sarcoma, esophageal cancer, and head and neck cancer. Overexpression of these two factors has been associated with increased processes involved in carcinogenesis, such as invasion, migration, epithelial-mesenchymal transition (EMT), angiog...
Source: Cytokine - September 6, 2020 Category: Molecular Biology Authors: Serafim Junior V, Fernandes GMM, Oliveira-Cucolo JG, Pavarino EC, Goloni-Bertollo EM Tags: Cytokine Source Type: research

Cancers, Vol. 12, Pages 334: TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
In conclusion, the carryover effects of olaparib to improve antitumor effect of subsequent irinotecan were demonstrated. These effects should be considered when determining the subsequent therapy with olaparib.
Source: Cancers - February 2, 2020 Category: Cancer & Oncology Authors: Jin Won Kim Ahrum Min Seock-Ah Im Hyemin Jang Yu Jin Kim Hee-Jun Kim Kyung-Hun Lee Tae-Yong Kim Keun Wook Lee Do-Youn Oh Jee-Hyun Kim Yung-Jue Bang Tags: Article Source Type: research

Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy.
Abstract LncRNA CASC11 promotes gastric cancer and colon cancer. Our study analyzed the role of CASC11 in ovarian squamous cell carcinoma (OSCC). In the present study we showed that plasma CASC11 was upregulated in OSCC, and the upregulation of CASC11 distinguished OSCC patients from control group. Plasma levels of CASC11 were further increased after chemotherapy. Treatment with oxaliplatin, tetraplatin, cisplatin, and carboplatin mediated the upregulation of CASC11 in cells of OSCC cell line. In addition, overexpression of CASC11 led to increased cancer cell viability under oxaliplatin, tetraplatin, cisplatin, an...
Source: Gene - June 6, 2019 Category: Genetics & Stem Cells Authors: Shen F, Feng L, Zhou J, Zhang H, Xu Y, Jiang R, Zhang H, Chen Y Tags: Gene Source Type: research

Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway
In conclusion, the present study elucidated that the activity of SMYD2 in NSCLC may affect the cell sensitivity to chemotherapeutic agents, especially to CDDP. The elevated SMYD2 mediated CDDP resistance and malignant phenotype in NSCLC, indicating that SMYD2 may be a useful biomarker of CDDP resistance in NSCLC. Inhibition of SMYD2 contributes to the methylation-related activation of p53 and thus results in cell apoptosis. Furthermore, combination treatment with CDDP and an SMYD2 inhibitor had a synergistically antitumor effects in a xenograft model in vivo. Given that SMYD2 has reversible effects and is a targetable prot...
Source: Frontiers in Oncology - April 25, 2019 Category: Cancer & Oncology Source Type: research

High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer
In this study, the immunohistochemistry results demonstrated that DEPDC1 was high-expressed in breast cancer tissues compared with the paired adjacent normal breast tissues, and its tendency at protein level was consistent with mRNA level from TCGA data. Moreover, DEPDC1 mRNA level revealed the strongest association with poor prognosis and development in breast cancer. In vitro assays showed that DEPDC1 overexpression resulted in significant promotion of proliferation by regulating cell cycle in MCF-7 cells, whilst an opposite effect was found in the MDA-MB-231 cells with DEPDC1 deletion. Notably, further investigation ind...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

Pages: 1  2  3